1198803-26-7

Basic information

• Product Name: N-(6-{6-chloro-5-[(phenylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-methyl-1,3-thiazole-4-carboxamide
• Synonyms: N-(6-{6-chloro-5-[(phenylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-methyl-1,3-thiazole-4-carboxamide
• CAS NO: 1198803-26-7
• Molecular Weight: 525.011
• Mol File: 1198803-26-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(6-{6-chloro-5-[(phenylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-methyl-1,3-thiazole-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-{6-chloro-5-[(phenylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-methyl-1,3-thiazole-4-carboxamide(1198803-26-7)
• EPA Substance Registry System: N-(6-{6-chloro-5-[(phenylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-methyl-1,3-thiazole-4-carboxamide(1198803-26-7)

Safety Data

• Hazardous Substances Data: 1198803-26-7(Hazardous Substances Data)

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 885518-46-7 6-bromo-4-nitro-1H-indazole 
• 914358-73-9 5-bromo-2-methylpyridin-3-ylamine 
• 588729-99-1 3-amino-5-bromo-2-chloropyridine 
• 885518-50-3 6-bromo-1H-indazole-4-amine 
• 1198436-89-3 N-(6-bromo-1H-indazol-4-yl)-2-methyl-1,3-thiazole-4-carboxamide 
• 1083326-17-3 N-(5-bromo-2-chloropyridin-3-yl)benzenesulfonamide 
• 1198437-65-8 2-methyl-N-[2-(tetrahydro-2H-pyran-2-yl)-6-(4,4,6,6-tetramethyl-1,3,2-dioxaborinan-2-yl)-2H-indazol-4-yl]-1,3-thiazole-4-carboxamide 
• 35272-15-2 2-methylthiazole-4-carboxylic acid 
• 55842-53-0 2-methyl-4-thiazolecarbonyl chloride 
• 1198437-61-4 N-[6-bromo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-y1]-2-methyl-1,3-thiazole-4-carboxamide 
• 1198437-57-8 6-bromo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-amine 
• 1198409-38-9 6-bromo-4-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole 
• 1198802-81-1 2-methyl-N-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide 

Relevant articles and documents

Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease

Optimization of lead compound 1, through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clinical candidates 2 (GSK2269557) and 3 (GSK2292767) for the treatment of respiratory indications via inhalation. Compounds 2 and 3 are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.